Companies developing hepatitis C virus treatments such as Inhibitex (INHX), Idenix (IDIX) and Achillion (ACHN) are moving lower after Pharmasset (VRUS) said it will amend the design of its QUANTUM Phase 2b trial. Pharmasset announced that it detected laboratory abnormalities associated with liver function in subjects receiving PSI-938 300 mg once daily.
Also ReadInvestors will grapple next week with major U.S. economic reports and the looming possibility of a Greek exit from …
There are no comments yet